CVE:AQS

Aequus Pharmaceuticals Stock Forecast, Price & News

C$0.12
0.00 (0.00 %)
(As of 09/20/2021 03:10 PM ET)
Add
Compare
Today's Range
C$0.12
C$0.12
50-Day Range
C$0.11
C$0.15
52-Week Range
C$0.09
C$0.29
Volume68,000 shs
Average Volume346,237 shs
Market CapitalizationC$15.92 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AQS News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.24 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Aequus Pharmaceuticals (CVE:AQS) Frequently Asked Questions

What stocks does MarketBeat like better than Aequus Pharmaceuticals?

Wall Street analysts have given Aequus Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aequus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aequus Pharmaceuticals' next earnings date?

Aequus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 29th 2021.
View our earnings forecast for Aequus Pharmaceuticals
.

How has Aequus Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Aequus Pharmaceuticals' stock was trading at C$0.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AQS stock has increased by 9.1% and is now trading at C$0.12.
View which stocks have been most impacted by COVID-19
.

Who are Aequus Pharmaceuticals' key executives?

Aequus Pharmaceuticals' management team includes the following people:
  • Mr. Douglas Glen Janzen, Chairman, CEO & Pres (Age 52, Pay $211.88k)
  • Ms. Ann Fehr CGA, CPA, CFO & Corp. Sec. (Age 52, Pay $111.1k)
  • Mr. Stuart Fowler, Strategic Commercial Advisor & Independent Director
  • Mr. Grant Larsen, Chief Commercial Officer

Who are some of Aequus Pharmaceuticals' key competitors?

What other stocks do shareholders of Aequus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include GrowLife (PHOT), Unrivaled Brands (TRTC), Abbott Laboratories (ABT), Acorn Energy (ACFN), Crown Castle International (CCI), Charlotte's Web (CWBHF), (FIRE.V) (FIRE), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Planet 13 (PLNHF).

What is Aequus Pharmaceuticals' stock symbol?

Aequus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "AQS."

How do I buy shares of Aequus Pharmaceuticals?

Shares of AQS and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Aequus Pharmaceuticals' stock price today?

One share of AQS stock can currently be purchased for approximately C$0.12.

How much money does Aequus Pharmaceuticals make?

Aequus Pharmaceuticals has a market capitalization of C$15.92 million and generates C$2.61 million in revenue each year.

How many employees does Aequus Pharmaceuticals have?

Aequus Pharmaceuticals employs 10 workers across the globe.

What is Aequus Pharmaceuticals' official website?

The official website for Aequus Pharmaceuticals is www.aequuspharma.ca.

Where are Aequus Pharmaceuticals' headquarters?

Aequus Pharmaceuticals is headquartered at 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada.

How can I contact Aequus Pharmaceuticals?

Aequus Pharmaceuticals' mailing address is 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada. The company can be reached via phone at +1-604-3367906.


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.